Clinical Trial Update: Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Anti-Tac labeled with Yttrium-90 (90Y-HAT) for Hodgkin lymphoma, Non-Hodgkin lymphoma, and lymphoid leukemia. The study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoid Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Anti-Tac (90Y-HAT) (90Y-labeled anti-Tac monoclonal antibody)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hodgkin's Disease, Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-12-07